1. Urinary cyclic nucleotide excretion was studied in 51 patients with malignant tumours and in 24 control subjects.
Introduction
Adenosine 3' : 5'-cyclic monophosphate (cyclic AMP) and guanosine 3' : 5'-cyclic monophosphate (cyclic GMP) act as second messengers for a number of agents, including peptide hormones, catecholamines and prostaglandins. Changes in cyclic nucleotide metabolism in many animal and human malignancies have been reported (Criss, 1974; Ryan & Heidrick, 1974; Hunt & Martin, 1980) . It has been suggested that such changes are determinants of the abnormal growth of tumours, but the evidence from studies in oivo usually does not support this (Hunt & Martin, 1980) . The cyclic nucleotide content of tumours may be subnormal, normal or supranormal and, theoretically, deviations could be reflected in the amounts of cyclic AMP and cyclic GMP in the body fluids of tumour-bearing animals or patients. Rats bearing some types of transplantable hepatomas and kidney tumours were found to have markedly increased rates of urinary excretion of cyclic GMP (Murad, Kimura, Hopkins, Looney & Kovacs, 1975; Criss & Murad, 1976) . Furthermore, there was some degree of correlation with the growth rate of the tumours and with their response to therapy. A small group of patients with hepatoma also had rates of urinary cyclic AMP excretion which were above the normal range (Neethling & Shanley, 1976) . The concentrations of cyclic GMP in the cerebrospinal fluid of patients with cerebral tumours are elevated (Trabucchi, Cerri, Spano & Kumakura, 1977) . Thus cyclic nucleotides had potential as 'tumour markers' and the present study was undertaken to examine this further in a spectrum of malignancies.
Methods
An unselected series of 5 1 patients with malignancies was studied over a 6 month period. Twenty of these (14 males, ages 15-67 years; six females, ages 3 1-62 years) had malignancies of the haemopoietic system and 3 1 (1 1 males, ages 15-72 years; 20 females, ages 27-68 years) had solid tumours, chiefly of epithelial origin. Some patients were hospitalized and others were not. Fifteen out of 20 of the patients with malignancies of the haemopoietic system and 26 out of 3 1 of the patients with solid tumours were receiving chemotherapy. None had received radiation therapy in the previous 9 months. Control subjects were 11 males, aged 21-56 years, and 13 females, aged 21-59 years. The age ranges of the control subjects were not significantly different from those in patients. Control subjects were in normal health and maintained a normal routine. Alcohol was not permitted. Tea and coffee consumption was not restricted as minor quantities of methylxanthines (e.g. caffeine) do not influence urinary cyclic AMP excretion (Murad & Pak, 1972; Broadus, 1977) .
Urine samples were collected over 24 h because cyclic nucleotide excretion varies diurnally (Murad & Pak, 1972; Sagel, Colwell, Loadholt & Lizarralde, 1973; Broadus, 1977; Kopp, Lin & Tucci, 1977) . Samples were collected into 10 ml of acetic acid (1 molh) and stored at 4°C for up to 7 days. Aliquots were then diluted with water and stored frozen. Preliminary studies showed that purification of urine samples before assay of the cyclic nucleotide content was not necessary. Cyclic AMP and cyclic GMP concentrations in urine were measured separately by radioimmunoassay (Steiner, Wehmann, Parker & Kipnis, 1972) . Antisera were raised in rabbits. The tyrosine methyl ester derivatives of succinyl cyclic AMP and succinyl cyclic GMP (Sigma Chemicals, St Louis, Mo., U.S.A.) were labelled with lZsI (The Radiochemical Centre, Amersham, Bucks, U.K.) as described by Steiner et al. (1972) . Assay incubations were initiated by addition of antibody and continued overnight at 4OC. Bound and free cyclic nucleotide fractions were separated with charcoal (Harper & Brooker, 1975) ; both fractions were counted for radioactivity in a Packard Auto Gamma counter. The specificity of the assay for cyclic AMP was determined. The concentrations of nucleotides required to produce half-maximal displacement of tracer were: cyclic AMP, 1 arbitrary unit; cyclic GMP, > l@ units; adenosine 5'-triphosphate, 10' units; adenosine 5'-diphosphate, 5 x 10' units; adenosine 5'-monophosphate, lo6 units; guanosine 5'-diphosphate, >4 x lo7 units; guanosine 5'-triphosphate, > 4 x lo7 units. For the assay of cyclic GMP, the corresponding values were: cyclic GMP, 1 unit; guanosine 5'-diphosphate, lo4 units; guanosine 5'-monophosphate, 2.5 x lo4 units; guanosine 5'-triphosphate, 2.5 x lo4 units; adenosine, 4 x 10' units; cyclic AMP, adenosine 5'-mono-, di-and tri-phosphates, > lo6 units. The absence of non-specific interference was established by: (1) demonstrating parallelism between assay standard curve and serial dilutions of samples; (2) demonstrating full recovery of known amounts of unlabelled cyclic nucleotides added to samples; (3) demonstrating > 95% abolition of assay reactivity of samples by prior incubation with phosphodiesterase.
Creatinine concentrations were assayed by the method of Bonsnes & Taussky (1945) . Cyclic nucleotide values were expressed per g of creatinine. All determinations were performed in triplicate and repeated at least once in a separate assay. Some of the data from controls and patients were not normally distributed. Where necessary, values were logarithmically transformed before comparison of groups by Student's t-test.
Results
The control values for cyclic nucleotide excretion were similar to those reported before (Table 1) . There were no significant correlations between age and cyclic nucleotide excretion rates or between cyclic AMP and cyclic GMP excretion rates in control subjects or in patients. 
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In female patients with malignancies the cyclic AMP excretion rate (3.31 f 2.60 pmol/g of creatinine) was not significantly different from that in control subjects. The group with solid tumours (3.31 f 2.96 pmol of cyclic AMP/g of creatinine) and that with haemopoietic malignancies (3.33 f 0.58 pmol/g of creatinine), considered separately, also had normal cyclic AMP excretion rates. In male patients, cyclic AMP excretion rate was normal in the group as a whole (3.17 & 8.83 pmol/g of creatinine) and in those with haemopoietic malignancies (2.10 1-20 pmol/g of creatinine) or with solid tumours (4.34 f 12.47 pmollg of creatiniie).
In contrsst, cyclic GMP excretion rate was markedly above the normal range in some patients with malignancies. For solid tumours, six out of 11 male and four out of 20 female patients had cyclic GMP excretion rates above the normal range. The difference in excretion rate between the male solid-tumour group and the controls was significant ( Table 2 ). This was also true for male patients with malignant melanoma or myeloid tumours. Both male and female groups of patients with lymphoid tumours had significantly elevated cyclic GMP excretion rates ( Table 2) .
Discussion
Cyclic nucleotide metabolism in human and animal tumours is frequently abnormal. The changes which have been demonstrated are extremely variable (Hunt & Martin, 1980) . The reported values for human tumour cyclic nucleotide content are particularly dimcult to interpret because rapid tissue fixation is not possible. This problem can be reduced by careful studies of the disappearance rate of cyclic nucleotides from excised human tissues Studies with tumour-bearing animals demonstrated normal urinary cyclic AMP excretion, with increased urinary cyclic GMP excretion in some cases (Murad et al., 1975; Criss & Murad, 1976) . The same pattern was observed in the present study. Although the cyclic AMP content of some human tumours, notably breast carcinomas, has been reported to be very high (Hunt & Martin, 1980) , this is not reflected in increased urinary excretion. A number of factors, including stress (Moyes 8c Moyes, 1977), depression and hospitalization (Naylor, Stansfield, Whyte & Hutchison, 1974) are suggested to perturb urinary cyclic AMP excretion. Decreased cyclic AMP excretion in malignancy has been reported (Gennari et al., 1978) but we could not confirm this.
Urinary cyclic GMP excretion was supranormal in 25 of 51 patients studied. Since the majority of patients were receiving chemotherapy it is possible that the abnormalities in cyclic GMP excretion were a result of the treatment rather than the disease. However, no correlations were found between individual drugs or regimens and cyclic GMP excretion. Untreated patients did not have significantly lower cyclic GMP excretion than that of treated patients. Furthermore, the increased excretion of cyclic GMP was unlikely to be a simple consequence of cell death because urinary cyclic AMP was normal. Cellular concentrations of cyclic AMP are 5-20 times cellular concentrations of cyclic GMP.
In animals, tumour cyclic GMP content is often higher than in control tissues. Furthermore, the activity of guanylate cyclase (the enzyme which catalyses the production of cyclic GMP from guanosine 5'6phosphate) is high in some, though not all, human tumours (Kim er al., 1977; Kumakura, Frattola, Spano & Trabucchi, 1977; Vesely & Levey, 1977) . Cyclic GMP excretion was particularly high in patients with lymphoid tumours; in only two out of 20 cases was the excretion rate below the mean control values. It is known that human lymphocytes, both normal and leukaemic, possess no cyclic GMP phosphodiesterase activity (Takemoto, Lee, Kaplan & Appleman, 1978) . Thus changes in the production of cyclic GMP in these cells could not be compensated for by alterations in the activity of the enzyme for which it is substrate. Murine leukaemia lymphocytes have markedly enhanced cyclic GMP phosphodiesterase activity (Hait & Weiss, 1977) . It should be noted that there is no direct evidence to suggest that the excess urinary cyclic GMP is produced by the tumour cells themselves. It is possible that tumour products could stimulate cyclic GMP production in normal tissues.
The clinical studies which have been carried out to date are too small to indicate whether urinary cyclic GMP excretion will be of use as a tumour marker, but this seems unlikely in view of the overlap of values from cancer patients with those from controls. In individuals with markedly increased cyclic GMP excretion it would be of interest to determine whether this varied during treatment and with tumour regression or recurrence. This has not been done. Determination of cyclic AMP and cyclic GMP concentrations in plasma might provide a more direct indication of abnormal tumour cyclic nucleotide metabolism; such a study is in progress. Further experiments are needed to determine the source of the excess urinary cyclic GMP in animals and in man.
